GSK announces $2.2 billion deal, targeting once-per-three-month food allergy drug
GSK has announced a $2.2 billion acquisition of RAPT Therapeutics, targeting a new food allergy drug, ozureprubart, which requires administration once every three months. The deal's effective cost is $1.9 billion after accounting for RAPT's cash reserves. RAPT's shares surged 64% in premarket trading, while GSK's shares fell 1% in London. The new drug aims to provide an alternative for patients who are ineligible for existing therapies, which require more frequent injections.
Dow Jones·
